ArticleFrontiers in immunology2025
Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma.
Bingxin Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it